Related by context. All words. (Click for frequent words.) 79 HBV DNA 77 viral load 77 IU mL 76 copies mL 75 HIV RNA 73 serum HCV RNA 73 plasma HCV RNA 71 serum HBV DNA 71 undetectable HCV RNA 70 copies ml 69 log# 68 virologic response 67 viral loads 66 HBV DNA levels 66 log# copies mL 66 viral suppression 66 detectable HCV RNA 66 sustained virologic response 66 log# reduction 65 undetectable viral load 65 virologic failure 65 mg kg dose 64 viremia 64 HCV viral 63 undetectable HBV DNA 63 complete cytogenetic 63 adefovir 63 Crohn Disease Activity 62 HBeAg seroconversion 62 HbA1c levels 62 virological response 62 undetectable virus HCV 62 virologic response EVR 62 CD4 + cell 61 IFN α 61 cEVR 61 fasting plasma glucose FPG 61 CDAI score 61 alanine aminotransferase ALT 61 HBeAg 61 evaluable patients 61 IU ml 61 HbA1c 61 rapid virologic response 60 HBeAg positive patients 60 virologic 60 timepoint 60 mg QD 60 -#.# log# 60 mcg kg 60 sustained virological response 60 complete cytogenetic response 60 antibody titers 60 HCV infected 60 HBsAg 60 eGFR 60 CD4 cell 60 plasma uric acid 60 seropositive patients 60 sUA 60 peginterferon 60 titers 60 viral titer 59 evaluable 59 serum phosphorus 59 baseline HbA1c 59 peripheral blood mononuclear 59 neutrophil counts 59 serum creatinine 59 ribavirin therapy 59 Index CDAI 59 CCyR 59 SVR# 59 MADRS score 59 LVEF 59 null responders 59 biochemical relapse 59 fasting plasma glucose 59 ng dL 59 pCR 59 lactate dehydrogenase LDH 59 plus ribavirin 59 mg TID 59 CR nPR 59 median PFS 59 plasma viremia 59 progression TTP 59 lumbar spine BMD 59 seroconversion 59 neutralizing antibodies 58 lopinavir r 58 pegylated interferon 58 Cmax 58 alanine aminotransferase 58 cytogenetic response 58 antiretroviral naive 58 ALT normalization 58 CRp 58 IPSS 58 antibody titer 58 pg mL 58 dosing cohorts 58 CD4 + T 58 Virologic 58 HCV genotype 1 58 lamivudine 58 disease progression 58 plasma concentrations 58 genotypic resistance 58 FEV1 58 liver histology 58 CD4 T 58 HBeAg negative patients 58 mg BID 58 atazanavir ritonavir 58 HAQ DI 58 free survival PFS 58 CDAI 58 PASI scores 58 chlorambucil 58 virologic breakthrough 58 mg dose 58 peg IFN 58 inflammatory lesions 57 IFN alpha 57 p = #.# [004] 57 ABC/3TC 57 CD4 + 57 serum phosphate 57 proteinuria 57 neutrophil count 57 platelet counts 57 mg/m2 dose 57 PegIFN RBV 57 response CCyR 57 PSADT 57 NNRTI resistance 57 serum urate 57 plasma glucose 57 Index CDAI score 57 HBeAg positive 57 nonresponders 57 Viral load 57 mcg BID 57 imatinib therapy 57 μmol L 57 antiviral activity 57 log# IU mL 57 severe neutropenia 57 REYATAZ r 57 PSA nadir 57 peginterferon alfa 2a 57 undetectable viral loads 57 CIMZIA TM 57 annualized relapse 57 p = #.# [002] 57 ug dose 57 antibody responses 57 Sustained virologic response 57 endoscopic remission 57 evaluable subjects 57 biochemical recurrence 57 experienced virologic failure 57 imatinib 57 ACR# response 57 Psoriasis Area 57 serum potassium 57 lopinavir r arm 57 secondary endpoint 57 viraemia 57 Solid Tumors criteria 57 LEXIVA r 57 bcr abl 57 entecavir 57 dose cohorts 57 serum creatinine levels 56 Tumor shrinkage 56 PEG IFN 56 lactate dehydrogenase 56 ribavirin RBV 56 partial remissions 56 HCV genotype 56 RNA copies mL 56 viral kinetics 56 serum testosterone 56 pg ml 56 tumor recurrence 56 RGT arm 56 QTcF 56 virological suppression 56 glomerular filtration rate 56 Median PFS 56 tipranavir ritonavir 56 lymphocyte counts 56 clodronate 56 dose cohort 56 TDF FTC 56 ritonavir boosted 56 specific antigen PSA 56 prospectively defined 56 tumor regression 56 posaconazole 56 A1C levels 56 #mg BID [002] 56 docetaxel 56 administered subcutaneously 56 virologic responses 56 P = .# 56 Hb A1C 56 mcg dose 56 estimated glomerular filtration 56 paraprotein 56 atheroma volume 56 telbivudine 56 HbA 1c levels 56 HCV Genotype 56 thyroglobulin 56 platelet reactivity 56 Pegasys ® 56 splenectomized patients 56 median CD4 56 baseline A1C 56 mucosal healing 56 mcg mL 56 liver metastases 56 HCV 56 SCr 56 TNFalpha 56 serum aminotransferase levels 56 HCV replicon 55 abacavir lamivudine 55 resected pancreatic cancer 55 nucleoside naive 55 interferon alfa 55 tumor shrinkage 55 prespecified 55 -#.# mg dL [002] 55 spontaneous bowel movements 55 aspartate aminotransferase AST 55 Median progression 55 microliter 55 troponin T 55 hours postdose 55 glycosylated hemoglobin HbA1c 55 #.#ng/ml 55 achieved ACR# 55 statistically significant p 55 creatinine levels 55 creatinine ratio 55 serum ALT 55 LPV r 55 Response Evaluation Criteria 55 binary restenosis 55 elevated ALT 55 cells μL 55 4mg/kg 55 remission CR 55 mitoxantrone 55 antigen PSA levels 55 APTIVUS r 55 Negative Syndrome 55 bortezomib 55 serum clusterin levels 55 lymphocyte count 55 OADs 55 plus methotrexate 55 HCV genotypes 55 CD4 55 HAART 55 Peg IFN 55 serum urate levels 55 leukocyte count 55 HbA1C 55 transgene expression 55 cells mcL 55 μg doses 55 oblimersen 55 mg RDEA# 55 RECIST criteria 55 REYATAZ r arm 55 FLT3 ITD 55 hepatitis C genotype 55 receiving VICTRELIS 55 g dL 55 sUA levels 55 coinfected 55 #mg BID [003] 55 serum concentrations 55 mg/m2 55 neutralizing antibody 55 cTnT 55 cells uL 55 glycated hemoglobin HbA1c 55 μg kg 55 decitabine 55 antiviral efficacy 55 low dose cytarabine 55 glycated hemoglobin levels 55 ng mL 55 cytogenetic responses 55 peginterferon alfa 2b 55 radiographic progression 55 urinary albumin 55 dacarbazine 55 complete remissions 54 Kaplan Meier analysis 54 cART 54 glycosylated hemoglobin 54 creatinine clearance 54 #mg/day [001] 54 nM 54 lymphocytosis 54 fosamprenavir 54 -#.# log# copies mL 54 certolizumab 54 RECIST Response Evaluation Criteria 54 XIENCE V PROMUS Stent 54 ng ml 54 nelfinavir 54 dose limiting toxicities 54 IFN gamma 54 mEq L 54 CD4 lymphocyte count 54 IGFBP 54 IgM 54 CD4 counts 54 undetectable viral 54 achieved PASI 54 plus dexamethasone 54 insulin detemir 54 virologic suppression 54 HSCT 54 dapagliflozin plus 54 serum prostate 54 blood Phe levels 54 #mg QD [002] 54 viral RNA 54 HbA 1c 54 IgG antibodies 54 KRAS mutations 54 8mg/kg 54 hemoglobin concentrations 54 lamivudine refractory patients 54 μg dose 54 posttreatment 54 HER2 expression 54 d4T 54 mRCC 54 blood Phe 54 nmol liter 54 dose cytarabine 54 seroprotection 54 aspartate aminotransferase 54 linezolid 54 CR CRu 54 pegylated interferon alpha 54 lung metastasis 54 iPTH 54 hemoglobin Hb 54 undetectable hepatitis C 54 peginterferon alfa 54 refractory NSCLC 54 μg ml 54 achieved sustained virological 54 Bcl xL 54 seronegative 54 EDSS score 54 mutated KRAS 54 mcg albinterferon alfa 2b 54 IgG antibody 54 K ras mutations 54 bortezomib refractory 54 mg ustekinumab 54 Secondary endpoints 54 placebo p 54 immunostaining 54 adalimumab 54 sunitinib 54 nephrotoxicity 54 raltegravir 54 DAPT 54 p = .# [002] 54 hemoglobin concentration 54 ACR# responses 54 PEG Interferon alfa 54 Telbivudine 54 JAK2 V#F 54 postintervention 54 aminotransferase levels 54 standard chemotherapy regimen 54 CCR5 tropic HIV 54 Median survival 54 ribavirin 54 calculated creatinine clearance 54 pmol L 53 #mg BID [001] 53 renal function 53 achieved undetectable HCV 53 CLL cells 53 creatinine 53 Pegasys plus Copegus 53 baseline FEV 53 ascending dose 53 aminotransferases 53 YMRS 53 seroconverted 53 5-FU/LV 53 anemia hemoglobin 53 mIU mL 53 piperacillin tazobactam 53 virological failure 53 achieved CCyR 53 dasatinib 53 serum calcium 53 mg/m2/day 53 Free Survival PFS 53 TMC# r 53 tipranavir 53 mg kg 53 interferon 53 primary endpoint 53 amprenavir 53 posttransplant 53 hematologic toxicity 53 hemoglobin A1c HbA1c 53 lispro 53 BARACLUDE ® 53 fasting glucose levels 53 paricalcitol 53 n = 53 lopinavir 53 relapsed MM 53 CD8 responses 53 #.#mg/dL 53 infliximab 53 Solid Tumors RECIST 53 baseline LDH 53 randomized #:# 53 castration resistant prostate cancer 53 FOLFOX4 53 serum PSA 53 Knodell necroinflammatory score 53 patients evaluable 53 HI titers 53 nitazoxanide 53 nucleotide analog 53 plasma renin activity 53 Elitek 53 treatment naïve genotype 53 secondary efficacy endpoints 53 mRNA expression 53 CD4 cells 53 CK # plasma concentrations 53 trastuzumab 53 neoadjuvant chemotherapy 53 rapid virological response 53 octreotide LAR 53 viral titers 53 daunorubicin 53 comparator PI r 53 EBMT criteria 53 EGFRvIII 53 recurrent genital herpes 53 transaminases 53 PBMCs 53 azacytidine 53 PREZISTA r 53 FOLFOX 53 cobicistat 53 achieved sustained virologic 53 ADAS cog 53 prior relapsers 53 genotype 1b 53 treatment naive genotype 53 PREZISTA ritonavir 53 CANCIDAS 53 p = #.# [003] 53 antiviral therapy 53 fasting insulin 53 LDL C 53 PCa 53 timepoints 53 FluCAM 53 achieve sustained virologic 53 cells/mm3 53 IL 1ß 53 serum uric acid 53 q#h 53 A1C 53 HCV RESPOND 2 53 pharmacodynamic 53 NIHSS 53 vicriviroc 53 cytotoxicity 53 interferon alpha 53 Montgomery Asberg Depression 53 Scale EDSS 53 DAS# [002] 53 HCV SPRINT 53 ALT flares 53 achieved statistical significance 53 corticosteroid dose 53 hepatitis C virus 53 tolvaptan 53 prior chemotherapy regimens 53 Secondary endpoints included 53 #.#/#.# mm Hg [003] 53 Expanded Disability Status 53 FOLFOX6 53 Sustained Virological Response 53 HGS ETR1 53 secondary efficacy endpoint 53 % CI #.#-#.# [003] 53 monotherapy 53 interferon alfa 2a 53 Partial Responses 53 oral glucose tolerance 53 nucleoside naive patients 53 mL/min/#.# m 2 53 EGFR TKI 53 moderate renal impairment 53 HDRS 52 tPSA 52 KRAS mutant tumors 52 clinically meaningful improvement 52 mg qd 52 mCi kg 52 CD4 + cells 52 anti HBs 52 mg dL 52 NPH insulin 52 CMV infection 52 baseline CD4 52 irbesartan 52 HPV-#/# 52 p = 52 ertapenem 52 serum phosphate levels 52 serum phosphorous 52 HAM D# scores 52 #.#/#.# mmHg [001] 52 histologically 52 placebo p = 52 hsCRP levels 52 Flu Cy 52 CD4s 52 LEXIVA 52 primary efficacy endpoint 52 intravascular hemolysis 52 EDSS scores 52 TIMP 52 hemoglobin A1c levels 52 incontinence episodes 52 CD# + [002] 52 hepatoma 52 SUVmax 52 retinal thickness 52 Traficet EN 52 CrCl 52 hepatic insulin sensitivity 52 randomization 52 cTnI 52 iloprost 52 bosentan 52 enfuvirtide 52 CK MB 52 limiting toxicity 52 peg interferon 52 serum calcium levels 52 mmHg 52 #mg/m# [001] 52 viremic 52 A1c levels 52 imetelstat 52 nodular partial response 52 bevirimat 52 Kaplan Meier estimate 52 titer 52 Scale EDSS score 52 AZT zidovudine Retrovir 52 Primary endpoints 52 CsA 52 #mg/day [002] 52 vWF 52 aminotransferase ALT 52 serum IGF 52 androgen deprivation 52 PANSS 52 lymphopenia 52 adefovir treated 52 pyrazinamide 52 receiving prophylactic anticoagulation 52 plus MTX 52 Sustained Virologic Response 52 Secondary endpoints include 52 univariate analysis 52 castrate resistant 52 fasting glucose 52 CMV disease 52 telomerase activity 52 febrile neutropenia 52 CIN3 52 sitagliptin 52 NRTI 52 MMSE score 52 colorectal liver metastases 52 inotropic 52 Peginterferon Alfa 2a 52 topotecan 52 #mmHg [001] 52 uM 52 K#N 52 definite stent thrombosis 52 lanthanum carbonate 52 T#I [002] 52 ascending doses 52 TIMP 1 52 plus prednisone 52 amoxicillin clavulanate 52 viral replication 52 apolipoprotein B 52 nanomolar 52 fluvastatin 52 serum cortisol 52 SELENA SLEDAI score 52 μM 52 pharmacokinetic PK profile 52 alfa 2a 52 darunavir ritonavir 52 tipranavir r 52 Rapid Virologic Response 52 saline placebo 52 HOMA IR 52 % Confidence Interval 52 Naive Patients 52 Kaplan Meier estimates 52 gp# [001] 52 fasting blood glucose 52 docetaxel chemotherapy 52 TNF α 52 neostigmine 52 lamivudine monotherapy 52 HER2/neu 52 mutated K ras 52 CLL SLL 52 viral tropism 52 serum phosphorus levels 52 ALND 52 placebo 52 OGTT 52 pegylated interferon alfa 2a 52 clusterin 52 HBeAg negative 52 engraftment 52 plasma leptin 52 postdose 52 dsDNA 52 active comparator 52 metastatic renal cell carcinoma 52 mL/min/#.# m2 52 Aptivus ® 52 Solid Tumors 52 PegIFN 52 receiving APTIVUS r 52 dose dexamethasone 52 antitumor activity 52 pegylated interferon alfa 2b 52 FOLFIRI 52 ACR Pedi 52 placebo dexamethasone 52 PEG Intron 52 Neutrophil 52 -#.# mg dL [001] 52 neurologic progression 52 #mg QD [001] 52 IIIa inhibitor 52 pegylated interferon alfa 52 ≥ 52 fulvestrant 52 ug kg 51 alkaline phosphatase 51 response pCR 51 triacylglycerol 51 telaprevir dosed 51 indinavir 51 degarelix 51 placebo fluoxetine 51 #mg/m# [002] 51 nicardipine 51 Gleevec resistant 51 autoantibody levels 51 NAbs 51 adjunctive placebo 51 fructosamine 51 K#R [002] 51 platelet aggregation 51 recurrent glioblastoma multiforme 51 F FDG PET 51 rituximab 51 Hb 51 mm Hg systolic 51 alkylating agent 51 locoregional disease 51 azacitidine 51 BENICAR HCT 51 IgG 51 A1c 51 NMIBC 51 IRLS score 51 mmHg systolic 51 ng dl 51 DLTs 51 ug mL 51 heavily pretreated 51 serum CRP 51 PROMACTA 51 CSBMs 51 IDX# 51 pulmonary arterial 51 peginterferon alfa 2a #KD 51 ERK activation 51 systemically administered 51 metabolic parameters 51 sipuleucel T 51 Pharmacokinetics PK 51 Recurrence Score 51 Alzheimer Disease Assessment 51 % CI #.#-#.# [007] 51 mcg doses 51 glycated hemoglobin 51 transaminase levels 51 distant metastasis 51 interferon IFN 51 KRAS mutation 51 parasitaemia 51 gout flares 51 nab paclitaxel 51 gadolinium enhancing lesions 51 adalimumab Humira 51 NNRTI 51 microg 51 desvenlafaxine succinate 51 comparator arm 51 Fludara 51 mmol l 51 interquartile range 51 hematological parameters 51 #mg/kg [002] 51 histologic 51 serum antibody 51 Pharmacokinetic parameters 51 leukopenia 51 DAS# remission 51 Lantus ® 51 virologic failures 51 Dasatinib 51 tumor regressions 51 oral allopurinol 51 LANTUS R 51 UACR 51 ISENTRESS 51 leukemic cells 51 nutlin 3a 51 p# activation 51 Decitabine 51 graft dysfunction 51 PREZISTA r arm 51 #ug [001] 51 VIRAMUNE 51 metastatic CRC 51 goserelin 51 R# #mg BID 51 darunavir r 51 clinically meaningful 51 pegIFN 51 prospectively stratified 51 mcg Albuferon 51 statistically significant improvement 51 myeloperoxidase 51 olmesartan 51 elevated transaminases 51 etanercept 51 IFN γ 51 antiretroviral naïve 51 preintervention 51 Gag polymorphisms 51 % CI #.#-#.# [006] 51 NRTIs 51 mesalamine granules 51 T2 lesions 51 Akt activation 51 serum sodium 51 albumin excretion 51 DMARD 51 KRAS wild 51 octreotide 51 CIMZIA TM certolizumab pegol 51 eosinophil count 51 distant metastases 51 laboratory abnormalities 51 activated partial thromboplastin 51 urine NGAL 51 oral FTY# 51 trough FEV1 51 bronchoalveolar lavage fluid 51 urine albumin 51 natriuretic peptides 51 bladder carcinoma 51 aminotransferase elevations greater 51 colorectal carcinoma 51 glucocorticoid 51 Chronic Hepatitis C 51 unfractionated heparin UFH 51 intramuscular dose 51 PEG Interferon lambda 51 demonstrated statistically significant 51 COPEGUS 51 #mg dose [001] 51 potent antiretroviral therapy 51 UGT#A# * 51 alteplase 51 BRAF mutation 51 interleukin IL -6 51 infarct size 51 FLT3 51 rheumatoid factor 51 Navelbine 51 CLA supplementation 51 thyroid stimulating hormone 51 CD4 + CD# 51 NT proBNP concentrations 51 concomitant medications 51 NOAEL 51 chemoradiotherapy 51 trastuzumab Herceptin ® 51 FOXP3 51 CSBM 51 mIU ml 50 leukocytosis 50 CD# upregulation 50 mcg QD 50 mg simvastatin 50 transaminase 50 cytarabine daunorubicin 50 fibrinolysis 50 SCIg 50 Diffuse Large B 50 intratumoral 50 HLA DR2 50 nadolol 50 composite endpoint 50 corrected QT interval 50 serum PTH 50 d dimer 50 metastatic RCC 50 inhibitor RG# 50 Score DAS# 50 invasive aspergillosis 50 alpha 2a 50 EpCAM expression 50 leukemia AML 50 noninferiority 50 ACTEMRA TM 50 PegIntron 50 viral kinetic 50 sweat chloride 50 idarubicin 50 caspofungin 50 valopicitabine 50 anthracycline taxane 50 Viral Load 50 replicon 50 aprepitant 50 ADCS ADL 50 lumbar spine bone 50 mg Lucentis 50 flutamide 50 #mg dose [002] 50 glycemia 50 glycosylated hemoglobin levels 50 NIH CPSI 50 null responder HCV 50 tirofiban 50 interferon alfa 2b 50 normotensive 50 serologically active patients 50 Platelet counts 50 endogenous EPO 50 IELT 50 naïve HCV 50 renal allograft 50 noncarriers 50 lung metastases 50 protease inhibitor mutations 50 Monotherapy 50 mg dl 50 steroid dexamethasone 50 PaO 2 50 neutralizing antibody responses 50 systolic dysfunction 50 FOLPI 50 serum albumin 50 HGS ETR2 50 pharmacokinetic parameters 50 EGFR mutations 50 glomerular filtration 50 fraction LVEF 50 #μg [002] 50 carboplatin paclitaxel 50 LAB GHRH 50 SBMs 50 estramustine 50 TMC# [001] 50 mycophenolate mofetil 50 ADAS Cog 50 hemoglobin A1C 50 HAART regimen 50 follicle stimulating hormone FSH 50 BCR ABL 50 Kaplan Meier survival 50 statistical significance p 50 Virological 50 intracranial hemorrhage ICH 50 randomized 50 Adalimumab 50 adenoma 50 SIV infection 50 aPTT 50 ramipril 50 Infected Patients 50 relapsers 50 intact parathyroid hormone 50 serum potassium levels 50 mmol L 50 Treatment Naive Patients 50 Pegylated Interferon 50 preoperative chemotherapy 50 pegylated liposomal doxorubicin 50 IgA 50 plasma urate 50 pulmonary exacerbations 50 tamsulosin 50 darunavir 50 CYP#A# substrate 50 epoetin beta 50 Target Lesion Revascularization TLR 50 Baseline characteristics 50 cTnT levels 50 immunological responses 50 intramuscularly 50 dosing cohort 50 Antiviral Activity 50 ACR# [002] 50 lipoprotein Lp 50 bFGF 50 advanced adenomas 50 lenalidomide 50 multivariate Cox 50 Immunohistochemical analysis 50 IGFBP 3 50 immunosuppression 50 recurrent VTE 50 hypophosphatemia 50 serum glucose 50 atazanavir 50 urinary N telopeptide 50 follicular NHL 50 XIENCE V demonstrated 50 macroalbuminuria 50 oxycodone CR 50 MCyR 50 GnRH agonist 50 BEACOPP 50 CCL#L# 50 mTSS 50 BARACLUDE 50 Rating Scale MADRS 50 survivin 50 VICTRELIS 50 low dose ritonavir 50 G CSF 50 mapatumumab 50 albuminuria 50 hypoglycemic events 50 ALT elevations 50 β blockers 50 extrapyramidal symptoms 50 Capacity FVC 50 HCV antibody 50 CD# expression [002] 50 pegylated interferon peg IFN 50 blood phenylalanine Phe 50 oral antidiabetic medication 50 HAART regimens 50 CIMZIA ™ 50 IFN alfa 50 insulin degludec 50 haematological toxicity 50 chronic HCV infection